BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a biotechnology company that specializes in developing innovative stem cell therapies for neurodegenerative diseases, faced a setback as the U.S. Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee delivered a verdict on the Biologics License Application (BLA) for NurOwn.

The company's investigational mesenchymal stem cell therapy candidate for the treatment of amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig's Disease, failed to garner substantial evidence of effectiveness in treating mild to moderate ALS, as indicated by the Committee's vote.

In other news, Accenture plc (NYSE: ACN), a leading global professional services company, reported fourth-quarter fiscal 2023 adjusted earnings of $2.71 per share, surpassing the consensus EPS estimate of $2.66. The company's quarterly revenues reached $15.98 billion, falling slightly short of analysts' expectations of $16.07 billion in revenue.

For the full-year fiscal 2024, Accenture anticipates adjusted EPS in the range of $11.97 to $12.32, contrasting with the consensus EPS estimate of $12.46 for the period.

In pre-market, $ACN was trading at $305.75, down $8.63 (-2.75%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)